Amneal Pharmaceuticals (AMRX) Trading 10.5% Higher

Share on StockTwits

Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) traded up 10.5% during trading on Tuesday . The stock traded as high as $9.50 and last traded at $9.13. 2,276,502 shares changed hands during mid-day trading, an increase of 124% from the average session volume of 1,018,064 shares. The stock had previously closed at $8.26.

Several analysts have commented on the stock. Raymond James upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research note on Tuesday. They noted that the move was a valuation call. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, May 7th. BMO Capital Markets decreased their price target on shares of Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Zacks Investment Research upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 8th. Finally, SunTrust Banks assumed coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $19.60.

The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. The stock has a market cap of $2.73 billion, a PE ratio of 8.68, a PEG ratio of 0.54 and a beta of 1.31.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.07). The business had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. As a group, analysts forecast that Amneal Pharmaceuticals Inc will post 0.95 EPS for the current year.

In other Amneal Pharmaceuticals news, VP Andrew S. Boyer bought 19,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $9.46 per share, for a total transaction of $179,740.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Peter R. Terreri sold 23,345 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total transaction of $289,244.55. The disclosure for this sale can be found here. Insiders have bought a total of 58,000 shares of company stock worth $590,790 over the last 90 days. Corporate insiders own 26.34% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cresset Asset Management LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 1st quarter valued at about $29,000. Bessemer Group Inc. purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $34,000. NumerixS Investment Technologies Inc raised its position in Amneal Pharmaceuticals by 52.1% in the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock worth $42,000 after purchasing an additional 1,045 shares during the period. Quantamental Technologies LLC purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $68,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Amneal Pharmaceuticals by 28.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock worth $91,000 after purchasing an additional 1,477 shares during the period. Hedge funds and other institutional investors own 37.81% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Amneal Pharmaceuticals (AMRX) Trading 10.5% Higher” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4350728/amneal-pharmaceuticals-amrx-trading-10-5-higher.html.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: Dividend Aristocrat Index

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ooma Inc  CFO Sells $64,302.06 in Stock
Ooma Inc CFO Sells $64,302.06 in Stock
Norman Gennaro Sells 752 Shares of Zendesk Inc  Stock
Norman Gennaro Sells 752 Shares of Zendesk Inc Stock
Richard Rappaport Sells 3,000 Shares of Skechers USA Inc  Stock
Richard Rappaport Sells 3,000 Shares of Skechers USA Inc Stock
Sailpoint Technologies Holdings Inc  Director Sells $80,000.00 in Stock
Sailpoint Technologies Holdings Inc Director Sells $80,000.00 in Stock
James Franklin Sells 50,000 Shares of Ur-Energy Inc.  Stock
James Franklin Sells 50,000 Shares of Ur-Energy Inc. Stock
Gordon R. Bernard Sells 8,876 Shares of Cumberland Pharmaceuticals, Inc.  Stock
Gordon R. Bernard Sells 8,876 Shares of Cumberland Pharmaceuticals, Inc. Stock


© 2006-2019 Ticker Report